Literature DB >> 15899212

[Dyspnea, oliguria and lower extremities edema in a patient undergoing mediastinic radiotherapy for a non-resectable thymic carcinoma].

Ignacio Gil-Bazo1, Pedro Azcárate Agüero, Leire Arbea Moreno, Marta Moreno Jiménez, José Esteban Salgado Pascual, Jesús García-Foncillas, Salvador Martín-Algarra.   

Abstract

In this case report we present the clinical signs and symptoms of cardiac tamponade of tumor origin. We explain the clinical investigations for its diagnosis as well as its specific differential diagnosis in cancer patients. The different therapeutic options are also presented together with a brief summary of the thymic carcinoma.

Entities:  

Mesh：

Year:  2005        PMID： 15899212     DOI： 10.1007/bf02710013

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN： 1699-048X            Impact factor:   3.405


  10 in total

1.  Electrical alternans in cardiac tamponade.

Authors:  E Kosta; I Kronzon
Journal:  Echocardiography       Date:  2000-08       Impact factor: 1.724

2.  Fluorodeoxyglucose positron emission tomography excludes pericardial metastasis by recurrent lung cancer.

Authors:  Nasrin V Ghesani; Xinhui Sun; Hongming Zhuang; Joseph W Sam; Abass Alavi
Journal:  Clin Nucl Med       Date:  2003-08       Impact factor: 7.794

3.  Stage III thymoma: pattern of failure after surgery and postoperative radiotherapy and its implication for future study.

Authors:  M Myojin; N C Choi; C D Wright; J C Wain; N Harris; E B Hug; D J Mathisen; T Lynch; R W Carey; M Grossbard; D M Finkelstein; H C Grillo
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-03-01       Impact factor: 7.038

4.  Occult thymic carcinoma presenting as malignant cardiac tamponade.

Authors:  Y Ando; N Hirabayashi; H Minami; F Nomura; S Sakai
Journal:  Intern Med       Date:  1995-05       Impact factor: 1.271

5.  Changes in QRS voltage in cardiac tamponade and pericardial effusion: reversibility after pericardiocentesis and after anti-inflammatory drug treatment.

Authors:  C Bruch; A Schmermund; N Dagres; T Bartel; G Caspari; S Sack; R Erbel
Journal:  J Am Coll Cardiol       Date:  2001-07       Impact factor: 24.094

6.  Chemotherapy for advanced thymic carcinoma: clinical response to cisplatin, doxorubicin, vincristine, and cyclophosphamide (ADOC chemotherapy).

Authors:  Thomonobu Koizumi; Yasuki Takabayashi; Satoshi Yamagishi; Kenji Tsushima; Akemi Takamizawa; Akihiro Tsukadaira; Hiroshi Yamamoto; Yoshitaka Yamazaki; Shinji Yamaguchi; Keisaku Fujimoto; Keishi Kubo; Yoshiki Hirose; Jirou Hirayama; Hisanori Saegusa
Journal:  Am J Clin Oncol       Date:  2002-06       Impact factor: 2.339

7.  New WHO histologic classification predicts prognosis of thymic epithelial tumors: a clinicopathologic study of 200 thymoma cases from China.

Authors:  Gang Chen; Alexander Marx; Wen-Hu Chen; Jiang Yong; Bernhard Puppe; Philipp Stroebel; Hans Konrad Mueller-Hermelink
Journal:  Cancer       Date:  2002-07-15       Impact factor: 6.860

8.  Cardiac tamponade as a presentation of malignant thymoma.

Authors:  R J Venegas; N C Sun
Journal:  Acta Cytol       Date:  1988 Mar-Apr       Impact factor: 2.319

9.  Treatment and prognosis of thymic carcinoma: a retrospective analysis of 40 cases.

Authors:  Kazuhiko Ogawa; Takafumi Toita; Takashi Uno; Nobukazu Fuwa; Yasumasa Kakinohana; Minoru Kamata; Kageharu Koja; Takao Kinjo; Genki Adachi; Sadayuki Murayama
Journal:  Cancer       Date:  2002-06-15       Impact factor: 6.860

10.  Undifferentiated epithelial-rich invasive malignant thymoma: complete response to cisplatin, vinblastine, and bleomycin therapy.

Authors:  C Dy; F A Calvo; J P Mindán; L A Aparicio; S M Algarra; A Gil; F González; S Harguindey
Journal:  J Clin Oncol       Date:  1988-03       Impact factor: 44.544
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.